Phase II Study of Florbetaben (BAY94-9172) PET Imaging for Detection/Exclusion of Cerebral β-amyloid.
Status:
Completed
Trial end date:
2011-01-01
Target enrollment:
Participant gender:
Summary
To determine the sensitivity of the visual assessment of BAY94-9172 PET images in detecting
cerebral β-amyloid in individuals with Down Syndrome (DS) and specificity in individuals
without DS. Given that individuals with Down Syndrome develop β-amyloid pathology over the
age of 40, the clinical diagnosis of Down Syndrome will serve as the standard of truth.